NESFROTAMIG
UNII 8YNA3QG3DS

Substance Identification & Data

This profile provides standardized clinical and technical data for Nesfrotamig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 8YNA3QG3DS.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2966936-23-0 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

8YNA3QG3DS

CAS Registry Number

2966936-23-0

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

NESFROTAMIG

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C192011

National Cancer Institute reference terminology for clinical and research data.

INN ID

13381

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Nesfrotamig

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Nesfrotamig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Nesfrotamig

Common Names & Synonyms

H-gamma1 heavy chain anti-ERBB2 fused to a scFvlh anti-TNFRSF9 (1-719) [H-gamma1 heavy chain anti-ERBB2 humanized (1-450) [VH (Homo sapiens IGHV3-66*01 (81.6%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.13] (26-33.51-58.97-109)) (1-120)-Homo sapiens IGHG1*03v (100%) G1m3>G1m17, nG1m1 CH1 K120, CH3 E12, M14 (CH1 R120>K (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121-450)] -18-mer enneakis (glycylseryl) linker (451-468) -scFvlh anti-TNFRSF9 Homo sapiens (469-719), 11-scFv-v2 C120 (VL)-C49 (VH) [V-LAMBDA (Homo sapiens IGLV1-47*02 (91.8%) -IGLJ2*01 (90.9%) VL G120>C (571), CDR-IMGT [8.3.11] (493-501.519-521.558-568)) (469-578) -20-mer tetrakis(tetraglycyl-seryl) linker (579-598) -VH (Homo sapiens IGHV3-23*01 (93.9%) -IGHD -IGHJ4*01 (100%) VH G49>C (642), CDR-IMGT [8.8.14] (624-631.649-656.695-708)) (599-719)]]; (223-214')-disulfide with L-kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-39*01 (86.3%) -IGKJ1*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (153'), V101 (191')) (108'-214')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1, lacking the glutamine synthetase (GS-KO) gene, glycoform alfa

HER2/4-1BB bispecific antibody, YH32367

Immunoglobulin G1, bispecific, anti-(human/Macaca fascicularis epidermal growth factor receptor HER2) (human-Mus musculus monoclonal YH32367 γ1-chain) fusion protein with peptide linker ((GS)9) fusion protein with immunoglobulin anti-(human/Macaca fascicularis tumor necrosis factor receptor TNFRSF9) (human single-chain variable fragment VL-(GGGGS)4-VH), disulfide with human-Mus musculus monoclonal YH32367 κ-chain, dimer

immunoglobulin (H-gamma1-scFvlh_L-kappa) dimer, anti-[Homo sapiens ERBB2 (receptor tyrosine-protein kinase erbB-2, epidermal growth factor receptor 2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)] and anti-[Homo sapiens TNFRSF9 (TNF receptor superfamily member 9, 4-1BB, T cell antigen ILA, CD137)], humanized and Homo sapiens monoclonal antibody; bispecific, tetravalent

nesfrotamig [INN]